Medivation reports Q1 EPS (18c), consensus (9c)
moreView todays social media effects on MDVNView the latest stocks trending across Twitter. Click to view dashboardSee who Medivation is hiring next, click here to view […]
MDVN
MEDIVATION, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
moreView todays social media effects on MDVNView the latest stocks trending across Twitter. Click to view dashboardSee who Medivation is hiring next, click here to view […]
Medivation Reports First Quarter Financial Results and Provides Corporate Update
[Marketwired] – Medivation, Inc. today provided a corporate update and reported its financial results for the first quarter ended March 31, 2014. U.S. net sales of XTANDI® capsules for the quarter, as reported by Astellas, … moreView todays social media effects on MDVNView the latest stocks trending across Twitter. Click to view dashboardSee who Medivation is hiring next, click here […]
Q1 2014 Medivation, Inc. Earnings Release – After Market Close
moreView todays social media effects on MDVNView the latest stocks trending across Twitter. Click to view dashboardSee who Medivation is hiring next, click here to view […]
Memorial Sloan-Kettering’s Dr. Howard Scher Reaffirms Commitment to Lead Phase I Trials for AV Therapeutics’ Prostate Cancer Drug
[GlobeNewswire] – NEW YORK — AV Therapeutics, Inc. (AV Therapeutics or the Company) (OTCQB:AVTH), a developer of cancer therapeutics and vaccines, announced Howard Scher, MD, Chief, Genitourinary … moreView todays social media effects on MDVNView the latest stocks trending across Twitter. Click to view dashboardSee who Medivation is hiring next, click here to view […]
Tuesday’s Top Health Care Stories: Bayer, Merck, Medivation, and AstraZeneca
moreView todays social media effects on MDVNView the latest stocks trending across Twitter. Click to view dashboardSee who Medivation is hiring next, click here to view […]
Astellas and Medivation Receive Priority Review from FDA for XTANDI® (Enzalutamide) Capsules In Chemotherapy-Naive Advanced Prostate Cancer
[PR Newswire] – TOKYO and SAN FRANCISCO, May 6, 2014 /PRNewswire/ — Astellas Pharma Inc. (TSE:4503) and Medivation Inc. (MDVN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the supplemental New Drug Application moreView todays social media effects on MDVNView the latest stocks trending across Twitter. Click to view dashboardSee who Medivation is hiring […]
Astellas and Medivation Receive Priority Review From FDA for XTANDI(R) (Enzalutamide) Capsules in Chemotherapy-Naive Advanced Prostate Cancer
[Marketwired] – Medivation, Inc. and Astellas Pharma Inc. today announced that the U.S. Food and Drug Administration has accepted for filing the supplemental New Drug Application to extend the indication for XTANDI® capsules … moreView todays social media effects on MDVNView the latest stocks trending across Twitter. Click to view dashboardSee who Medivation is hiring next, click here to view […]
Why Earnings Season Could Be Great for Medivation (MDVN)
moreView todays social media effects on MDVNView the latest stocks trending across Twitter. Click to view dashboardSee who Medivation is hiring next, click here to view […]
4:10 pm Medivation enters into license agreement with OncoFusion for compounds targeting bromodomain proteins
moreView todays social media effects on MDVNView the latest stocks trending across Twitter. Click to view dashboardSee who Medivation is hiring next, click here to view […]
